Amarin Corp PLC(AMRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMRN Amarin Corp PLC

Trading 04-08 13:26:16 EDT

14.73

+0.04

+0.24%

High14.99	Low14.50	Vol11.72K
Open14.95	D1 Closing14.69	Amplitude3.34%
Mkt Cap306.17M	Tradable Cap276.18M	Total Shares20.79M
T/O172.34K	T/O Rate0.06%	Tradable Shares18.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AMRN","market":"US","secType":"STK","nameCN":"Amarin Corp PLC","latestPrice":14.725,"timestamp":1775669113661,"preClose":14.69,"halted":0,"volume":11718,"delay":0,"changeRate":0.0023825731790333656,"floatShares":18756131,"shares":20792684,"eps":-1.869855,"marketStatus":"Trading","change":0.035,"latestTime":"04-08 13:26:16 EDT","open":14.95,"high":14.99,"low":14.5,"amount":172344.148956,"amplitude":0.033356,"askPrice":14.8,"askSize":73,"bidPrice":14.7,"bidSize":45,"shortable":3,"etf":0,"ttmEps":-1.869855,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775678400000},"marketStatusCode":2,"adr":1,"adrRate":20,"listingDate":733640400000,"exchange":"NASDAQ","adjPreClose":14.69,"preHourTrading":{"tag":"盘前","latestPrice":14.99,"preClose":14.69,"latestTime":"09:03 EDT","volume":4,"amount":61.190004,"timestamp":1775653398590,"change":0.3,"changeRate":0.020422,"amplitude":0.041525},"postHourTrading":{"tag":"盘后","latestPrice":14.4,"preClose":14.69,"latestTime":"18:37 EDT","volume":1608,"amount":23158.04,"timestamp":1775601465895,"change":-0.29,"changeRate":-0.019741,"amplitude":0.019741},"volumeRatio":0.712783,"impliedVol":0.6079,"impliedVolPercentile":0.3253},"requestUrl":"/m/hq/s/AMRN/tweets","defaultTab":"tweets","newsList":[{"id":"2625941413","title":"BUZZ-Amarin rises as heart drug spotlighted at major cardiology meet","url":"https://stock-news.laohu8.com/highlight/detail?id=2625941413","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625941413?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:57","pubTimestamp":1775653065,"startTime":"0","endTime":"0","summary":"BUZZ-Amarin rises as heart drug spotlighted at major cardiology meet** Shares of drug developer Amarin AMRN.O rise 2.1% to $15 premarket** Co says new analyses reinforce benefits of Vascepa, its heart drug used to lower the risk of serious heart events in highrisk patients** Icosapent ethyl targets high triglycerides, a type of blood fat that can raise heart attack and stroke risk even when cholesterol is controlled - AMRN** Co says secondary analysis of its study showed fewer heartrelated events when the drug was added to standard statin therapy in the highestrisk patients** Updated U.S. cardiology guidelines flagged high triglycerides as an ongoing heart risk and recommend treatments beyond statins for some patients, while cautioning against routine fibrate use - AMRN** Drug is sold as Vascepa in the U.S. and Vazkepa in Europe and is approved in nearly 100 markets, co says** As of last close, stock up ~5% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL4N40R14Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625294697","title":"Amarin says REDUCE-IT post hoc analysis shows Vascepa cuts events in highest-risk patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2625294697","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625294697?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:04","pubTimestamp":1775649877,"startTime":"0","endTime":"0","summary":"Amarin highlighted new clinical findings on icosapent ethyl presented at ACC Scientific Sessions 2026, including a secondary post hoc analysis from REDUCE-IT.The analysis found icosapent ethyl, added to statin therapy, reduced cardiovascular events versus placebo in patients at extreme or very high cardiovascular risk.ACC 2026 discussions tied updated 2026 ACC/AHA/Multi-society dyslipidemia guidelines to ongoing residual cardiovascular risk despite LDL-C control, supporting complementary therapy use in patients with elevated triglycerides.Amarin also pointed to prior studies linking EPA-based therapy to favorable coronary plaque changes, positioning icosapent ethyl as a differentiated option beyond triglyceride lowering alone.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL45Z73D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4112","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4585","LU0314104364.USD","SG9999014013.SGD","AMRN","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","IE00BN0W2V16.EUR","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625294918","title":"American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2625294918","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625294918?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:00","pubTimestamp":1775649600,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., April  08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to advancing the science of cardiovascular disease (CVD) worldwi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3270041/18362/en/American-College-of-Cardiology-ACC-Scientific-Sessions-2026-Underscore-the-Need-for-Complementary-Therapies-Including-Icosapent-Ethyl-IPE-in-Treatment-of-Elevated-Triglycerides-and.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSII","CV","IPE","BK4117","BK4107","AFG","BK4585","BK4139","BK4153","BK4090","TG","BK4082","VGT","AMRN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623341038","title":"European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2623341038","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623341038?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:07","pubTimestamp":1774883261,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary kicked off the week higher late Monday morning, rising 0.78% to 1,700.55 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by petroleum refiner Equinor  and internet advertising firm Criteo , which rose 3.8% and 3.4%, respectively. They were followed by software firm SAP  and pharmaceutical company Novo Nordisk , which were up 1.4% each.The decliners from continental Europe were led by medical device maker EDAP TMS  and biopharmaceutical company Cellectis , which dropped 2.8% and 2.5%, respectively. They were followed by accommodations booking company trivago  and biotech firm BioNTech , which lost 1.8% and 0.4%, respectively.The gainers from the UK were led by pharmaceutical company AstraZeneca , which advanced by 2.9%. It was followed by pharmaceutical company Silence Therapeutics  and utilities company National Grid , which increased 2.4% and 2.3%, respectively.The decliners from the UK and Irel","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQNR","IE00BZ1G4Q59.USD","BK4505","WPP.AU","AMRN","IE00BKVL7J92.USD","MREO","BK4009","NVOX","BK4077","LU0320765992.SGD","AZN","BK4007","AFG","BK4139","LU2456880835.USD","BK4107","NVO.AU","BK4588","BK4208","SAP","NVOH","EDAP","BK4201","BK4585","IE00B3T34201.USD","BK4548","IHG","BK4117","BK4023","BK4613","LU2417539215.USD","CLLS","CRTO","LU0154236417.USD","WPP","BK4528","TRVG","BK4599","SLN","BK7104","BK4532","BK4551","LU2462157665.USD","BNTX","IE00BFMHRM44.USD","LU0058720904.USD","LU0109394709.USD","NGG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622803182","title":"Amarin board shrinks to seven directors; Paul Cohen and Oliver O'Connor exit ahead of 2026 annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2622803182","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622803182?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:01","pubTimestamp":1774645288,"startTime":"0","endTime":"0","summary":"Amarin said board members Paul Cohen and Oliver O'Connor will not stand for re-election at the 2026 annual shareholder meeting.Their resignations will take effect immediately before the meeting begins.The board also decided to reduce its size to seven directors from nine, effective at the same time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8m5C3H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621096131","title":"European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2621096131","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621096131?lang=en_us&edition=fundamental","pubTime":"2026-03-24 23:16","pubTimestamp":1774365369,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower late Tuesday morning, declining 0.31% to 1,701.97 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS  and telecommunications firm Nokia , which rose 2.1% and 2%, respectively. They were followed by petroleum refiner Equinor , which rose 1.2%.The decliners from continental Europe were led by biotech firm Evaxion  and software company SAP , which lost 4.6% and 4.4% respectively. They were followed by internet browser company Opera  and biopharmaceutical firm DBV Technologies , which fell 4.3% and 4.1% respectively.The gainers from the UK were led by oil and gas companies BP  and Shell , which advanced 2.1% and 1.5% respectively. They were followed by medical device maker Smith & Nephew  and biopharmaceutical company Amarin , which increased 1.4% and 1.2% respectively.The decliners from the UK and Ireland were led by Akari Therapeutics  and Biodexa P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BMPRXR70.SGD","LU2236285917.USD","AMRN","BK4023","SHEL","EVAX","LU0648005311.SGD","SHEH","BK4588","BK4134","BK4107","DBVT","IE00BMPRXN33.USD","BK4139","BK4613","LU0300736492.USD","LU0278409577.USD","BK4585","LU0320765646.SGD","OPRA","DAVA","AKTX","BK4020","BPH","EDAP","LU0300736062.USD","NOK","AFG","BK4547","LU0162691827.USD","BK4082","LNOK","BK4117","LU0098860793.USD","BDRX","SAP","DAVA.AU","SLN","BP","LU0084288595.USD","SNN","LU1162221912.USD","BK4201","LU1829250122.USD","EQNR","BK4007","LU0072461881.USD","BK4528"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244042","title":"European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244042","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244042?lang=en_us&edition=fundamental","pubTime":"2026-03-19 23:25","pubTimestamp":1773933927,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were down sharply late Thursday morning, as the S&P Europe Select ADR Index dropped 0.5% to 1,711.73.From continental Europe, the gainers were led by petroleum refiner Equinor  and oil and gas company Eni , which climbed 8.5% and 3.2% respectively. They were followed by pharmaceutical company Sanofi  and software firm SAP , which advanced 2.4% and 0.7% respectively.The decliners from continental Europe were led by lender Banco Santander  and biopharmaceutical company Grifols , which dropped 2.8% and 3.1% respectively. They were followed by telecommunications company Nokia  and biotech firm BioNTech , which were down 2% and 1.5% respectively.The gainers from the UK were led by oil and gas company BP  and biopharmaceutical company Amarin , which rose 4.3% and 1.3% respectively. They were followed by biotech company Trinity Biotech  and cruise line operator Carnival , which were up 0.9% and 0.6% respectively.The decliners ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BP","LU1829250122.USD","BK4107","NOK","LU0072461881.USD","EQNR","SAN.AU","BDRX","BK4547","AFG","BK4201","BK4521","GRFS","AMRN","BK4023","IE00BMPRXN33.USD","LNOK","BK4588","NCNA","BK4585","BK4551","SAN","BK4139","CUK","BPH","TRIB","BK4548","BK4082","AKTX","BK4142","BK4207","BK4613","IE00BMPRXR70.SGD","SLN","SAP","BK7142","LU0162691827.USD","LU1162221912.USD","BK4568","IE00BFXG1179.USD","BNTX","BK4007","BK4117","LU0320765646.SGD","BK4020","SNY","BK4528","E","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620255638","title":"Amarin cites 2026 ACC/AHA dyslipidemia guideline support for icosapent ethyl in statin-treated patients with elevated triglycerides","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255638","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255638?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:32","pubTimestamp":1773837135,"startTime":"0","endTime":"0","summary":"Amarin cites 2026 ACC/AHA dyslipidemia guideline support for icosapent ethyl in statin-treated patients with elevated triglycerides. The company stated that icosapent ethyl is the only FDA-approved oral therapy shown to reduce cardiovascular events by 25% when added to statins in high-risk patients with elevated triglycerides.Amarin said the guideline notes fenofibrates do not reduce cardiovascular risk when added to statins.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLcbdGh2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","AMRN","IE00BN0W2V16.EUR","NDAQ","LU2095319765.USD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014013.SGD","BK4112","LU2210150020.SGD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BN0W2W23.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619468488","title":"Amarin to present new REDUCE-IT subgroup analysis of icosapent ethyl at ACC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468488?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:15","pubTimestamp":1773663353,"startTime":"0","endTime":"0","summary":"Amarin said additional subgroup and mechanistic analyses related to the REDUCE-IT study will be presented at the American College of Cardiology’s Annual Scientific Session & Expo in New Orleans on March 28–30, 2026. An oral presentation titled “Efficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular Risk: A Secondary Analysis of REDUCE-IT” is scheduled for March 29, 2026. A poster titled “Rates of Lipoprotein Oxidation Increase at Elevated Levels in Non-linear Fashion and Inhibited by Eicosapentaenoic Acid ” is scheduled for March 28, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7FKQC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","AMRN","IE00BN0W2V16.EUR","NDAQ","LU2095319765.USD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014013.SGD","BK4112","LU2210150020.SGD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BN0W2W23.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619463448","title":"New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo","url":"https://stock-news.laohu8.com/highlight/detail?id=2619463448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619463448?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:15","pubTimestamp":1773663300,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., March  16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256251/18362/en/New-REDUCE-IT-Data-in-Patients-at-Extreme-Cardiovascular-Risk-and-In-Vitro-Research-on-the-Mechanistic-Effects-of-Eicosapentaenoic-Acid-EPA-on-Lipoprotein-a-Lp-a-Oxidation-to-be-Pr.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4588","BK4139","BK4117","CSII","VGT","BK4090","BK4585","IPE","BK4153","TG","AFG","BK4107","AMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616586787","title":"Amarin’s European Outlook Hinges on Recordati’s VAZKEPA Execution, Raising Commercial and IP Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2616586787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616586787?lang=en_us&edition=fundamental","pubTime":"2026-03-04 14:01","pubTimestamp":1772604062,"startTime":"0","endTime":"0","summary":"Amarin Corporation Plc (AMRN) has disclosed a new risk, in the Corporate Activity and Growth category. The analyst notes that Amarin’s revenue pros...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amarins-european-outlook-hinges-on-recordatis-vazkepa-execution-raising-commercial-and-ip-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amarins-european-outlook-hinges-on-recordatis-vazkepa-execution-raising-commercial-and-ip-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IP","BK4136","BK4585","LU2463526074.USD","LU1481600234.SGD","LU1481599808.USD","LU1169590202.USD","BK4588","LU1487256676.USD","LU1169589451.USD","AMRN","BK4139","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616327663","title":"Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death","url":"https://stock-news.laohu8.com/highlight/detail?id=2616327663","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616327663?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:03","pubTimestamp":1772456581,"startTime":"0","endTime":"0","summary":"Amarin post hoc REDUCE-IT analysis links icosapent ethyl to fewer hospitalizations and fewer days lost to hospitalization and death. Amarin Corporation plc announced the publication of a post hoc analysis of the REDUCE-IT trial in the European Journal of Preventive Cardiology. The analysis included 8,179 statin-treated participants with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors, randomized to icosapent ethyl 2 g twice daily or placebo and followed for a median of five years. According to the publication, icosapent ethyl was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death versus placebo. The results have already been presented in the peer-reviewed publication.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL2PYqkS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014005.SGD","BK4588","BK4585","SG9999014013.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","BK4139","BK4112","LU2095319765.USD","LU2210149790.SGD","NDAQ","SG9999014021.USD","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","AMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616330980","title":"Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330980","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330980?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456400,"startTime":"0","endTime":"0","summary":"Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/02/3247357/18362/en/Effects-of-Icosapent-Ethyl-on-Risk-and-Duration-of-Hospitalizations-and-Death-in-REDUCE-IT-Post-Hoc-Analysis-Published-in-the-European-Journal-of-Preventive-Cardiology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","VGT","POST","BK4588","TG","BK4153","BK4212","BK4585","IPE","BK4139","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614418720","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Ionis Pharmaceuticals (IONS) and Repligen (RGEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614418720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614418720?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109016,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amarin (AMRN – Research Report), Ionis Pharmaceuticals (IONS – Re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amarin-amrn-ionis-pharmaceuticals-ions-and-repligen-rgen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amarin-amrn-ionis-pharmaceuticals-ions-and-repligen-rgen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4585","LU0106261612.USD","BK4137","BK4588","XBI","HCSG","BK4121","IONS","LABU","LU0012050646.USD","XLV","BK4139","LU1815336091.USD","LU0757428866.USD","RGEN","LU0128526141.USD","AMRN","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614156031","title":"European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2614156031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614156031?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:16","pubTimestamp":1772036179,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 1% to 1,860.69 on the S&P Europe Select ADR Index.From continental Europe, the ga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4559","MREO","LU0300736062.USD","BK4585","BK7104","LU0124676726.USD","BK4107","BK4117","IE00BZ1G4Q59.USD","LU0128525689.USD","NVOH","LU1093756325.SGD","UN","LU0310800965.SGD","LU1093756168.USD","AUTL","BK4588","BK7119","IE00BKVL7J92.USD","00005","BK4592","BUD","DBVT","SAN","NVOX","BK7507","EVAX","BK4082","IHG","BHP","BK7511","BK4007","LU0052756011.USD","LU0689626769.HKD","BK4142","BK4207","BK4169","BK7095","BK4599","HSBH","LU0300736492.USD","LU1267930227.SGD","SQNS","BK4183","BK4158","LU0154236417.USD","BK7142","TRIB","ULVR.UK","BK4139","HSBC","DEO","BK4505","LU2236285917.USD","CLLS","AMRN","BK4168","UL","BK4141","DGE.UK","BK4521"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614817340","title":"Rpt-Amarin Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2614817340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614817340?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:19","pubTimestamp":1772021940,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL8N3ZL16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614081733","title":"Corrected-Amarin Q4 Revenue (Not 'Product REV') USD 49.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614081733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614081733?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:19","pubTimestamp":1772021940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL8N3ZL16W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614817510","title":"Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2614817510","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614817510?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:14","pubTimestamp":1772021690,"startTime":"0","endTime":"0","summary":"Peter Fishman, Amarin’s (AMRN) Chief Financial Officer, said, “Our fourth quarter performance reflects our early success in optimizing the Company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amarin-cfo-says-well-positioned-to-deliver-on-2026-strategic-priorities-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amarin-cfo-says-well-positioned-to-deliver-on-2026-strategic-priorities-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614089727","title":"Amarin Q4 net loss narrows to USD 1.2 million (97%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089727","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089727?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:03","pubTimestamp":1772021039,"startTime":"0","endTime":"0","summary":"Amarin Q4 net loss narrows to USD 1.2 million (97%)               Amarin reported Q4 2025 total net revenue of USD 49.2 million (down 21%), including net product revenue of USD 46.5 million (down 23%)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL48YSjh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014039.USD","BK4585","NDAQ","SG9999014013.SGD","BK4588","IE00BGHQF748.EUR","AMRN","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","BK4139","BK4112","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614089759","title":"Amarin Corp Q4 Adj. EPS $0.01 Beats $(0.56) Estimate, Sales $49.219M Miss $50.619M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089759","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089759?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:03","pubTimestamp":1772020981,"startTime":"0","endTime":"0","summary":"Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.56) by 101.79 percent. This is a 150 percent increase over losses of $(0.02) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50844422/amarin-corp-q4-adj-eps-0-01-beats-0-56-estimate-sales-49-219m-miss-50-619m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AMRN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amarincorp.com","stockEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0448},{"period":"3month","weight":0.047},{"period":"6month","weight":-0.2297},{"period":"1year","weight":0.8002},{"period":"ytd","weight":0.0527}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.121922},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.050693},{"month":3,"riseRate":0.484848,"avgChangeRate":0.002821},{"month":4,"riseRate":0.454545,"avgChangeRate":0.058745},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.012581},{"month":6,"riseRate":0.484848,"avgChangeRate":0.002623},{"month":7,"riseRate":0.25,"avgChangeRate":-0.030175},{"month":8,"riseRate":0.5625,"avgChangeRate":0.06306},{"month":9,"riseRate":0.4375,"avgChangeRate":0.077692},{"month":10,"riseRate":0.375,"avgChangeRate":-0.048639},{"month":11,"riseRate":0.5625,"avgChangeRate":0.109863},{"month":12,"riseRate":0.4375,"avgChangeRate":-0.023149}],"exchange":"NASDAQ","name":"Amarin Corp PLC","nameEN":"Amarin Corp PLC","securityTypeName":"DR","adrRate":"1:20"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amarin Corp PLC(AMRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amarin Corp PLC(AMRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amarin Corp PLC,AMRN,Amarin Corp PLC股票,Amarin Corp PLC股票老虎,Amarin Corp PLC股票老虎国际,Amarin Corp PLC行情,Amarin Corp PLC股票行情,Amarin Corp PLC股价,Amarin Corp PLC股市,Amarin Corp PLC股票价格,Amarin Corp PLC股票交易,Amarin Corp PLC股票购买,Amarin Corp PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amarin Corp PLC(AMRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amarin Corp PLC(AMRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction